covalent-design

Version Compatibility

Reference examples tested with: RDKit 2024.09+, OpenEye / AutoDock Vina 1.2+ (for covalent extensions), GOLD (commercial), DOCKovalent (web service), HCovDock 1.0+.

Before using code patterns, verify installed versions match. If versions differ:

• Python: pip show <package> then help(rdkit.Chem) to check signatures

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.

Covalent Inhibitor Design

" Design molecules that form covalent bonds with target protein residues. The "covalent revolution" made TCIs (Targeted Covalent Inhibitors) clinically validated: KRAS G12C inhibitors (sotorasib, adagrasib), BTK inhibitors (ibrutinib), and EGFR inhibitors (osimertinib) are recent successes. Postdoc-grade covalent design requires balancing intrinsic reactivity vs selectivity, reversibility (irreversible vs reversible covalent), and drug-likeness (warheads can hurt PK).

For warhead substructure filtering (in non-covalent contexts), see chemoinformatics/substructure-search. For non-covalent docking, see chemoinformatics/virtual-screening. For pose validation, see chemoinformatics/pose-validation.

Reactive Residue Taxonomy

Residue	% of covalent drugs	Reactivity	Notes
Cysteine	~98%	High (nucleophile thiol)	Most accessible; preferred
Lysine	~1%	Moderate (amine)	Less reactive; selective for sulfonyl fluoride
Serine	<1%	Low (alcohol, requires activation)	β-lactam, boronate
Threonine	very rare	Low	Boronate, aldehyde
Tyrosine	very rare	Moderate (phenol)	Sulfonyl fluoride, fluorosulfate
Aspartate/Glutamate	very rare	Low (carboxylate)	Aldehyde Schiff base

Cysteine is the dominant target because:

• Soft nucleophile (matches soft electrophiles)
• Low background reactivity (rare in proteins, ~1.7%)
• Distinguishable from common nucleophiles (GSH, off-target Cys)

Warhead Chemistry

Warhead	SMARTS	Reactivity	Reversibility	Cys-selective
Acrylamide	C(=O)C=C	Moderate (Michael acceptor)	Irreversible	Yes
Chloroacetamide	C(=O)CCl	High (SN2)	Irreversible	Yes
α-haloketone	[CX3](=O)C[F,Cl,Br]	Very high	Irreversible	Yes
Vinyl sulfone	S(=O)(=O)C=C	Moderate (Michael)	Irreversible	Yes
Sulfonyl fluoride	S(=O)(=O)F	Moderate	Irreversible	Lys/Tyr/Ser
Fluorosulfate (SuFEx)	OS(=O)(=O)F	Moderate	Irreversible	Tyr/Lys
Aldehyde	C(=O)[H]	Variable	Reversible	Cys/Lys/Ser
Boronate	B(O)O	Moderate	Reversible	Ser/Thr
Nitrile	C#N	Low	Reversible	Cys
Epoxide	C1OC1	High	Irreversible	Cys/Lys/Asp
Maleimide	C(=O)N(C(=O))C=C	Very high	Irreversible	Cys
Cysteine-selective heterocycle	various	Moderate	Variable	Yes

Practical hierarchy: Acrylamide is the modern default for cysteine-selective TCIs. Chloroacetamide is more reactive (faster) but less selective.

Decision Tree by Scenario

Goal	Warhead choice	Reactivity tier
Cysteine TCI, drug candidate	Acrylamide	Moderate (~kinact/Ki ~10^3-10^5 M^-1 s^-1)
Cysteine probe (chemical biology)	Chloroacetamide	High (~10^4-10^6 M^-1 s^-1)
Lysine TCI	Sulfonyl fluoride	Moderate
Tyrosine TCI	Fluorosulfate (SuFEx)	Moderate
Reversible covalent (KRAS G12C-like)	Acrylamide with α-substitution	Moderate reversibility

Intrinsic Reactivity Assays

A covalent inhibitor's effectiveness = (intrinsic reactivity) × (target residence time in pocket) / (off-target reactivity).

WARHEAD_PATTERNS = {
    'acrylamide': Chem.MolFromSmarts('[CX3]=[CX3][CX3]=O'),
    'chloroacetamide': Chem.MolFromSmarts('[CX3](=O)C[Cl]'),
    'vinyl_sulfone': Chem.MolFromSmarts('[SX4](=O)(=O)C=C'),
    'sulfonyl_fluoride': Chem.MolFromSmarts('[SX4](=O)(=O)F'),
}

def warhead_reactivity(mol):
    hits = []
    for name, pat in WARHEAD_PATTERNS.items():
        if mol.HasSubstructMatch(pat):
            hits.append(name)
    return hits

GSH Stability

Test the warhead's intrinsic reactivity against glutathione (γ-Glu-Cys-Gly) in silico before synthesis. A compound that reacts quickly with GSH reacts quickly with off-target thiols (Cys in other proteins).

GSH_SMILES = 'NC(CCC(=O)NCC(=O)O)C(=O)NCC(=O)O'
GSH = Chem.MolFromSmiles(GSH_SMILES)
GSH_CYS_S = [a.GetIdx() for a in GSH.GetAtoms() if a.GetSymbol() == 'S']

# Check warhead accessibility to Cys-SH in GSH
# Use docking or compute GSH-Warhead clash as proxy

For experimental GSH stability: HPLC-MS with GSH (1 mM) + compound (10 µM) at 37°C; measure t1/2 (high-quality TCIs have GSH t1/2 > 4 hours).

Reversible vs Irreversible Covalent

Property	Irreversible	Reversible
Binding kinetics	Single exponential	Two-step (k_on, k_off)
Residence time	t_res = 1/k_inact	t_res = 1/k_off
Off-target risk	Higher	Lower
Recovery after washout	No	Yes
Clinical examples	afatinib, ibrutinib	sotorasib (KRAS G12C α-cyanoacrylamide)

Reversible covalent is preferred when:

• Off-target Cys in related proteins is concern
• Long-term dosing required
• Pharmacodynamic response must be reversible

Covalent Docking Tools

Standard Vina/GNINA cannot predict covalent adducts. Covalent-specific tools:

Tool	Approach	Use
GOLD (CCDC)	Covalent bond constraint + ChemScore	Commercial; reliable
DOCKovalent	DOCK 6/7 covalent extension	Academic; web service
HCovDock	Hybrid covalent	Open source
CovSel (custom)	Enumerate covalent adducts then dock	Custom

Workflow: (1) Generate covalent adduct SMILES from warhead + target residue, (2) Build 3D structure, (3) Dock with covalent constraint.

# Conceptual covalent adduct generation
# Use RDKit reaction SMARTS to attach warhead to Cys-S-H
adduct_rxn = AllChem.ReactionFromSmarts(
    '[Cys-S-H:1].[CX3:2]=[CX3:3][CX3:4]=O>>[Cys-S:1][CX3:2][CX3:3][CX3:4]=O'
)

Per-Tool Failure Modes

Acrylamide too reactive in vivo

Trigger: Compound shows GSH t1/2 < 1 hour.

Mechanism: Acrylamide warhead reacts with off-target Cys.

Symptom: Off-target adducts, toxicity.

Fix: Reduce warhead reactivity (alpha-substituted acrylamide, e.g. KRAS G12C strategy); use Cyanoacrylamide for reversible covalent.

No covalent adduct formed in MS

Trigger: Compound has warhead, binds pocket, but no covalent adduct observed.

Mechanism: Warhead geometry wrong; nucleophile not in attack position.

Symptom: Reversible-only binding; no time-dependent IC50 shift.

Fix: Visualize docked pose; check distance nucleophile to electrophile < 4 Å; align with target residue.

Hook effect in PROTAC context

Trigger: PROTAC with covalent target ligand shows bell-shaped degradation curve.

Mechanism: At high PROTAC concentration, binary complexes (target-PROTAC, E3-PROTAC) dominate over ternary.

Symptom: Dmax falls at high [PROTAC]; no degradation.

Fix: Use lower dose window; optimize linker to favor ternary.

References

• Lonsdale & Ward, J. Med. Chem. -- targeted covalent inhibitors review.
• Singh et al. -- KRAS G12C and covalent drug design.
• Gehringer & Laufer, J. Med. Chem. -- cysteine-targeted warheads.

Related Skills

• chemoinformatics/substructure-search - Warhead SMARTS
• chemoinformatics/virtual-screening - Non-covalent docking
• chemoinformatics/protac-degraders - Bifunctional covalent
• chemoinformatics/pose-validation - Pose QC for covalent adducts